

Ref no: 206270418
From: [Public](#)
Date: 27/04/2018
Subject: Free of charge drug stock NICE funding

REQUEST

1. Has your trust accepted or is it currently accepting manufacturer provision of free of charge drug stock between licensing and NICE funding? [Yes/No]

No

2. Has your trust accepted or is it currently accepting the following list of drugs in psoriasis:

Brodalumab [Kyntheum]	[Yes/No]
Guselkumab [Tremfya]	[Yes/No]
Ixekizumab [Taltz]	[Yes/No]
Secukinumab [Cosentyx]	[Yes/No]

Not applicable

3. Has your trust accepted or is it currently accepting the following list of drugs in Rheumatoid Arthritis:

Tofacitinib [Xeljanz]	[Yes/No]
Baricitinib [Olumiant]	[Yes/No]
Golimumab [Simponi]	[Yes/No]
Certolizumab [Cimzia]	[Yes/No]
Apremilast [Otezla]	[Yes/No]
Tocilizumab [Ro Actemra]	[Yes/No]

Not applicable

4. Has your trust accepted or is it currently accepting the following list of drugs in Ankylosing Spondylitis or Psoriatic Arthritis:

Secukinumab [Cosentyx]	[Yes/No]
------------------------	----------

Not applicable

5. Has your trust accepted or is it currently accepting the following list of drugs in Ulcerative Colitis:

Golimumab [Simponi]	[Yes/No]
---------------------	----------

Not applicable

6. If your trust has not accepted manufacturer provision of free of charge drug stock, what have been the reasons for this?

We follow the Pan Mersey Area Prescribing Committee Policy

<http://www.panmerseyapc.nhs.uk/home/policies/T4.pdf>

7. In future, will your trust be able to accept manufacturer provision of free of charge drug stock? [Yes/No]

No

8. What is the preferred distribution channel for the provision of free of charge drug stock?

Homecare [Yes/No]

Delivered directly to hospital/Trust [Yes/No]

Other (please provide details)
[.....]

Not applicable

9. For how long is free of charge drug stock typically provided for each patient?

first dose [Yes/No]

first month [Yes/No]

first 3 months [Yes/No]

Other [.....]

Not applicable